Acne is one of the most common skin conditions in the world, and it can affect you at almost any stage of life. Although many people associate acne with the teenage years, hormonal changes mean you may continue to experience breakouts well into adulthood or even develop acne for the first time later in life. Traditional treatments such as topical retinoids, benzoyl peroxide, antibiotics and oral medicines have helped many people, but you may find that these options do not always provide the results you are looking for.
Hormones, particularly androgens, play an important role in acne development by stimulating your sebaceous glands to produce excess oil. When this extra oil combines with blocked pores, bacteria and inflammation, acne spots can develop. For many years, treatments that targeted hormones were mainly available as oral medicines, which may not have been suitable for everyone because of their wider effects on the body.
The development of clascoterone cream introduced a different approach to acne treatment. Rather than changing hormone levels throughout your body, clascoterone works directly within your skin by blocking androgen receptors in the areas where acne develops. This made it the first topical anti-androgen treatment approved specifically for acne vulgaris.
In this article, you will learn about the pivotal Phase III clinical trials that evaluated clascoterone 1% cream, what researchers discovered and what these findings could mean for you if you are considering newer treatment options for acne.
Understanding Acne Vulgaris
Acne vulgaris develops when your hair follicles become blocked with excess oil, dead skin cells and bacteria. If this happens, you may notice blackheads, whiteheads or inflamed spots forming on your skin. In some cases, acne can also cause deeper, painful nodules that take longer to heal and may increase the risk of scarring.
You are most likely to develop acne on areas where oil glands are more active, such as your face, chest, shoulders and back. The type and severity of acne can vary from person to person, so while you may experience only occasional breakouts, someone else may have more persistent or severe symptoms.
Although acne is extremely common, it can affect more than just your skin. If your breakouts are frequent or severe, they may have an impact on your confidence, emotional wellbeing and quality of life. Understanding how acne develops is an important first step towards finding a treatment plan that works for you.
The Role of Hormones in Acne
Hormones play a major role in the development of acne, which is why you may notice changes in your skin during different stages of life. Androgens, a group of hormones found in both males and females, stimulate your sebaceous glands to produce more sebum, the natural oil that helps protect your skin.
When your skin produces too much sebum, it can combine with dead skin cells and block your pores. This creates an environment where bacteria can grow more easily, leading to inflammation and the development of acne spots.
This hormonal influence helps explain why acne often becomes more noticeable during puberty and why you may continue to experience breakouts as an adult. It also highlights why researchers have explored treatments that target hormonal pathways directly within the skin, offering new options for managing acne.
Traditional Acne Treatments
For many years, acne treatment has relied on options such as topical creams, oral antibiotics, retinoids and hormonal medicines. If you have acne, your treatment plan may depend on the type and severity of your breakouts, as well as how your skin responds to previous therapies.
These treatments continue to be effective for many people, helping to reduce excess oil, prevent blocked pores, control bacteria and ease inflammation. However, you may find that your acne persists, returns after treatment or does not respond as well as expected, particularly if hormones are playing a significant role.
Because of these challenges, researchers have explored new ways to manage acne by targeting hormonal activity directly within the skin. This approach aims to treat acne where it develops, giving you additional treatment options without affecting hormone levels throughout the rest of your body.
What Is Clascoterone?
Clascoterone is a topical prescription cream that contains an androgen receptor inhibitor. If you are looking for a treatment that targets one of the underlying causes of acne, clascoterone offers a different approach from many traditional acne therapies.
Instead of changing hormone levels throughout your body, clascoterone works directly within your skin by blocking androgen receptors in the areas where acne develops. This helps reduce the effect of hormones that stimulate excess oil production, which can contribute to blocked pores and inflammatory spots.
This targeted mechanism represented a new direction in acne treatment. By acting locally where acne forms, clascoterone may provide another treatment option for people who need hormonal acne management without the broader effects associated with systemic hormonal medicines.
Why Were the Clascoterone Studies Conducted?
The Phase III clinical trials were carried out to evaluate how effective and safe clascoterone 1% cream is for treating acne vulgaris. If you are considering newer acne treatments, these studies provide important evidence about whether the cream can help improve your skin while maintaining an acceptable safety profile.
Researchers wanted to find out whether clascoterone could reduce both inflammatory and non-inflammatory acne lesions and improve the overall appearance of your skin when compared with a placebo cream. They also monitored participants closely to understand how well the treatment was tolerated and to identify any possible side effects.
These clinical trials formed an essential part of the regulatory approval process. The results helped determine whether clascoterone met the standards required for approval, giving you and your healthcare professional access to evidence-based information when considering treatment options for acne vulgaris.
Clinical Trial Design
The pivotal clascoterone studies were carefully designed to provide reliable evidence about how well the treatment worked and how safe it was. If you are interested in the research behind new acne treatments, it is important to know that these clinical trials followed strict scientific methods to produce trustworthy results.
Participants were randomly assigned to receive either clascoterone 1% cream or a matching vehicle cream. Because the trials were double-blind, neither participants nor investigators knew which treatment had been assigned during the blinded study period. Because the trials were double-blind, neither you nor the researchers would have known which treatment you were receiving during the study, helping to ensure the findings remained as unbiased as possible.
Throughout the trial, you would have attended regular assessments so researchers could monitor changes in your acne using standardised severity measurements. By comparing results between the two groups, researchers were able to determine whether clascoterone provided meaningful improvements and whether you could potentially benefit from this targeted treatment approach.
Who Took Part in the Research?
The clascoterone clinical trials included both adolescents and adults with facial acne vulgaris. If you are considering this type of treatment, it is helpful to know that the research involved people from different age groups, making the findings more relevant to a wider range of patients.
Participants had varying levels of acne severity that were considered suitable for evaluating a topical treatment. By including people with different degrees of acne, researchers could better understand how the cream performed across a broad spectrum of individuals who might use it in clinical practice.
This approach allowed researchers to assess whether the treatment worked consistently in different patient groups. As a result, you and your dermatologist can look at the study findings with greater confidence when discussing whether clascoterone may be an appropriate option for your acne management.
Clascoterone Phase III Trials: Key Facts
- Two identically designed Phase III trials evaluated clascoterone 1% cream for facial acne vulgaris.
- The trials were multicentre, randomised, double-blind and vehicle-controlled.
- Participants applied clascoterone 1% cream or vehicle cream twice daily for 12 weeks.
- The studies assessed inflammatory lesions, non-inflammatory lesions and overall acne severity.
- Treatment success required both a clear or almost-clear Investigator Global Assessment score and at least a two-grade improvement from baseline.
- The current UK indication is for people aged 12 years and over.
- Trial results describe average outcomes across study groups and do not predict exactly how one person will respond.
Research Insight: What Did the Pivotal Trials Find?
The pivotal trials showed that clascoterone produced greater improvements than vehicle cream across several acne outcomes.
At Week 12, IGA treatment success was achieved by 18.8% of participants receiving clascoterone compared with 8.7% receiving vehicle in Trial 1. In Trial 2, success rates were 20.9% with clascoterone and 6.6% with vehicle.
Researchers also found greater reductions in both inflammatory and non-inflammatory lesion counts with clascoterone. These findings show that targeting androgen-related activity within the skin can provide meaningful benefit for some patients.
However, it is important to interpret the results carefully. Even though clascoterone performed better than vehicle, most participants did not meet the strict IGA success definition by Week 12. Individual response can vary, and acne treatment still needs to be selected according to your acne severity, skin tolerance, previous treatment and wider medical circumstances.
Measuring Acne Improvement
To understand whether clascoterone was effective, researchers used recognised clinical scoring systems to measure changes in acne throughout the study. If you are taking part in a clinical trial or discussing treatment results with your dermatologist, these standardised assessments help ensure that improvements are measured consistently.
Researchers counted inflammatory lesions, such as papules and pustules, as well as non-inflammatory lesions, including blackheads and whiteheads. Researchers also assessed participants’ overall acne severity using the Investigator Global Assessment scale, providing another measure of response alongside inflammatory and non-inflammatory lesion counts.
By using these objective measurements, researchers were able to compare the treatment and control groups fairly and accurately. This approach provides evidence that helps you and your healthcare professional understand how well a treatment performs before it becomes part of routine acne care.
How the Clascoterone Trials Measured Treatment Success
| Trial Outcome | What Researchers Assessed | What Improvement Means |
| Investigator Global Assessment (IGA) | The overall severity of facial acne using a standard clinical grading scale | A lower severity grade indicates improvement in the overall appearance and severity of acne |
| IGA treatment success | Whether participants achieved clear or almost-clear skin together with at least a two-grade improvement from baseline | This represented the trial’s strict overall treatment-success endpoint |
| Inflammatory lesion count | Changes in lesions such as papules and pustules | A reduction indicates improvement in inflamed acne spots |
| Non-inflammatory lesion count | Changes in lesions such as blackheads and whiteheads | A reduction indicates improvement in blocked-pore acne lesions |
| Local skin tolerability | Reactions affecting the areas where the cream was applied | Helped researchers assess whether treatment-related skin reactions were manageable |
| Overall response at Week 12 | Combined assessment of acne severity and lesion changes after the treatment period | Allowed researchers to compare the active cream with vehicle under the same study conditions |
Using several outcome measures gave researchers a broader understanding of treatment response. Improvement in acne can involve fewer inflamed spots, fewer blocked pores and a change in overall disease severity, so the trial findings should be interpreted across these different outcomes rather than from one percentage alone.
Reduction in Acne Lesions
One of the main findings from the clinical trials was that clascoterone significantly reduced both inflammatory and non-inflammatory acne lesions. If you are looking for a treatment that targets one of the underlying causes of acne, these results showed that clascoterone could help improve different types of spots rather than focusing on just one.
Throughout the treatment period, many participants experienced noticeable improvements in the number and severity of their acne lesions. As treatment continued, you may expect gradual changes rather than immediate results, which is common with many prescription acne therapies.
These findings demonstrated that targeting androgen receptors directly within the skin could effectively reduce acne activity. By working where acne develops, clascoterone offers you a different treatment approach that addresses hormonal influences without altering hormone levels throughout the rest of your body.
Improvements in Overall Skin Appearance
In addition to counting the number of acne spots, researchers also looked at your overall skin appearance to determine how successful the treatment was. This gave a broader picture of how well clascoterone worked, rather than focusing only on individual lesions.
A higher proportion of participants receiving clascoterone achieved the strict IGA treatment-success endpoint than those receiving vehicle cream. However, most participants did not achieve this endpoint by Week 12, which is an important consideration when interpreting the results.
These improvements reflected both reduced inflammation and fewer visible lesions over the course of the study. As your skin becomes clearer, you may also notice improvements in confidence and day-to-day comfort, although individual results can vary from person to person.
How Clascoterone Differs from Other Treatments
Clascoterone works differently from many traditional acne treatments because it targets hormonal activity within the skin. Instead of focusing mainly on bacteria or skin cell turnover, it acts on androgen receptors involved in oil production and acne development. This gives dermatologists another option for selected patients.
- Targets Androgen Activity: Clascoterone blocks the effects of androgens directly within the skin where acne develops.
- Different from Antibiotics: It does not work by killing acne-causing bacteria, so its mechanism is different from antibiotic treatments.
- Different from Retinoids: Unlike retinoids, it does not primarily work by increasing skin cell turnover and preventing blocked pores.
- Adds Another Treatment Option: Its distinct mechanism may make it useful for some patients depending on acne type and treatment history.
Overall, clascoterone offers a different approach to acne treatment by targeting hormonal signalling in the skin. It may be suitable when your dermatologist believes this mechanism fits your acne pattern and treatment goals. Careful assessment remains important to decide whether it is the right option for you.
Safety Findings
The current UK prescribing information also includes precautions relating to local skin reactions and potential HPA-axis suppression under certain exposure conditions. These findings do not mean that every patient will experience such effects, but they reinforce the importance of using the treatment as prescribed and discussing ongoing treatment with your healthcare professional.
Most of the reported side effects were mild and occurred where the cream was applied. You might experience temporary skin irritation, redness or dryness, but these reactions were generally manageable and were monitored closely by the research team throughout the studies.
Overall, clascoterone demonstrated an acceptable safety profile during the clinical trials. Although your experience may differ from someone else’s, your dermatologist can explain the potential benefits and possible side effects, helping you decide whether this treatment is suitable for your individual needs.
Clinical Tip: Review Treatment Response Rather Than Continuing Automatically
Clascoterone is applied twice daily, but treatment response should still be reviewed. Current UK prescribing information advises considering reassessment at 12 weeks if treatment needs to continue or restart. Your clinician can review how your acne has responded, whether you are experiencing irritation or other concerns, and whether the treatment remains appropriate for you.
The Importance of Topical Hormonal Therapy
Before clascoterone became available, hormonal acne treatment generally relied on oral medicines that affected hormone activity throughout the body. If you were not able to take these treatments or they were not suitable for you, your options for managing hormone-related acne may have been more limited.
A topical anti-androgen offers a different approach by working directly within your skin, where acne develops. Instead of changing hormone levels throughout your body, it targets androgen receptors at the application site, helping to address one of the key factors involved in acne formation.
This approach may be particularly useful if you are not a suitable candidate for systemic hormonal therapy or if you are looking for an alternative treatment option. Your dermatologist can assess your individual needs and help you decide whether topical hormonal therapy could be an appropriate part of your acne management plan.
UK Guidance Note: Is Clascoterone Available in the UK?
Clascoterone cream is licensed in the UK for the topical treatment of acne vulgaris in people aged 12 years and over. Treatment suitability still depends on your age, acne pattern, previous treatment, skin tolerance and individual clinical circumstances.
NICE is currently unable to make an NHS technology-appraisal recommendation for clascoterone because the company did not submit evidence for that appraisal process. This should not be interpreted as NICE concluding that clascoterone does not work. It means that NICE did not complete a full appraisal and recommendation for NHS use.
If you are considering clascoterone, your dermatologist can explain current availability, whether it is appropriate for your acne and how it compares with other suitable treatment options.
Individualising Acne Treatment
No single acne treatment is right for everyone because every person’s skin and acne are different. If you are seeking treatment, your dermatologist will consider your individual circumstances rather than recommending the same approach for every patient.
Before suggesting a treatment, your doctor will assess factors such as the severity of your acne, your skin type, previous treatments, medical history and your personal preferences. By understanding how your acne affects you and how your skin has responded in the past, they can recommend the option that is most likely to meet your needs.
This personalised approach helps you receive a treatment plan that is tailored to your condition and lifestyle. With regular follow-up and adjustments when needed, you and your dermatologist can work together to achieve the best possible results for your skin.
Combining Clascoterone With Other Treatments
The pivotal Phase III trials evaluated clascoterone without concurrent acne treatments, so those studies do not by themselves establish the best combination regimen. Any combination approach should therefore be selected individually by your dermatologist.
Depending on your individual needs, you may be advised to use clascoterone with other topical therapies that target blocked pores, bacteria or inflammation. By combining treatments that work in different ways, your healthcare professional can develop a more comprehensive approach to managing your acne.
Combination treatment is often an important part of personalised acne care. Your dermatologist will consider your skin type, acne severity, previous treatment responses and overall treatment goals to create a plan that is tailored specifically for you and can be adjusted as your skin changes over time.
Ongoing Research
Research into acne continues to examine hormonal signalling, inflammation, treatment combinations and longer-term outcomes. For clascoterone specifically, longer-term follow-up and real-world evidence can help clarify how treatment performs beyond the controlled conditions of the pivotal 12-week trials.
Current research is exploring additional hormonal therapies, improved topical medicines and new ways to reduce inflammation while minimising side effects. These advances could provide you with treatments that are not only more effective but also easier to use and better suited to your individual needs.
As new evidence becomes available, you may have access to a wider range of acne treatments than ever before. This ongoing research is helping doctors offer more personalised care, giving you more options to manage acne successfully and improve the health and appearance of your skin.
Long-Term Acne Management
Acne often requires consistent treatment over several months, so it is important not to expect immediate results. If you are following a treatment plan, using your prescribed medicines regularly and as directed can give you the best chance of seeing gradual improvement.
Maintaining a regular skincare routine and attending follow-up appointments can also make a significant difference. Your dermatologist can monitor how your skin is responding, answer any questions you may have and adjust your treatment if your acne changes or you experience any side effects.
Long-term management is an important part of successful acne care. By staying consistent with your treatment and working closely with your healthcare professional, you can help reduce the likelihood of future flare-ups and support healthier, clearer skin over time.
The Impact of Clinical Trials
Large clinical trials play an essential role in bringing new treatments into everyday medical practice. If you are considering a newer acne therapy, the evidence from these studies helps you and your dermatologist understand how well a treatment works and how safe it is before it becomes widely available.
The clascoterone studies showed that blocking androgen receptors directly within the skin could be an effective way to manage acne. This research demonstrated that a topical anti-androgen could offer a different treatment approach by targeting one of the underlying hormonal factors involved in acne development.
The findings from these clinical trials have expanded the range of treatment options available for acne. As research continues, you may benefit from more personalised therapies that give you additional choices for managing your skin and achieving better long-term results.
The Future of Hormonal Acne Treatment
The success of clascoterone has encouraged researchers to continue exploring targeted treatments for hormonal acne. If you are living with acne, these advances may lead to more options that address the underlying causes of your breakouts rather than simply treating the visible symptoms.
As research progresses, your dermatologist may be able to recommend therapies based on the specific biological mechanisms driving your acne In the future, your dermatologist may be able to recommend therapies based on the specific biological mechanisms driving your acne, helping to match you with the treatment that is most suitable for your individual needs.
This represents an exciting direction for dermatology research and offers hope for even more effective acne management. As new treatments are developed and studied, you may benefit from therapies that provide better results, fewer unwanted effects and a more personalised approach to caring for your skin.
Seeking Specialist Acne Care
If acne is affecting your confidence, leaving scars or failing to improve with over-the-counter products, it may be time to speak with a dermatologist. A specialist can assess your skin, identify the type and severity of your acne, and help you understand which treatment options may be most suitable for you.
Modern acne therapies continue to expand, giving you more choices than ever before for managing both adolescent and adult acne. Whether your acne is influenced by hormones, inflammation or other factors, your dermatologist can recommend a personalised treatment plan based on your symptoms, medical history and treatment goals.
Seeking specialist advice early may also help reduce the risk of long-term scarring and persistent breakouts. By working closely with your healthcare professional, you can make informed decisions about your treatment and find an approach that supports clearer, healthier skin over the long term.
Myth vs Fact: Understanding Clascoterone for Acne
| Myth | Fact |
| Clascoterone changes hormone levels throughout your whole body. | Clascoterone is applied topically and primarily acts locally in the skin, with low systemic exposure. However, it should not be described as having absolutely no potential systemic effects, and it should be used according to prescribing guidance. |
| Because clascoterone is a topical cream, it cannot cause side effects. | Topical medicines can still cause side effects. Clascoterone may cause local reactions such as redness, dryness, itching or stinging, and prescribing information also includes additional safety precautions. |
| Clascoterone works instantly because it directly targets androgen receptors. | Acne treatment takes time. The pivotal trials assessed the main efficacy outcomes after 12 weeks of twice-daily treatment. Individual response can vary. |
| The Phase III trials showed that almost everyone achieved clear skin. | Clascoterone produced higher treatment-success rates than vehicle cream, but the strict clear or almost-clear success outcome was achieved by a minority of participants at Week 12. The results were clinically meaningful at a group level but do not guarantee complete clearance. |
| Clascoterone replaces every other acne treatment. | Acne treatment needs to be individualised. Different treatments target different aspects of acne, and the most suitable approach depends on acne severity, lesion type, scarring risk, previous treatment and individual tolerance. |
| A NICE non-recommendation means the treatment was proven ineffective. | NICE did not make a recommendation because the company did not submit evidence for the technology appraisal. That is different from NICE completing an appraisal and concluding that the medicine is clinically ineffective. |
Key Takeaways
- Clascoterone is a topical androgen receptor inhibitor developed for acne vulgaris.
- The two pivotal Phase III trials compared clascoterone 1% cream with vehicle cream over 12 weeks.
- The studies found greater improvement with clascoterone across IGA treatment success and inflammatory and non-inflammatory lesion outcomes.
- The treatment acts primarily within the skin and has low systemic exposure, but it should not be described as completely free from potential systemic or local effects.
- Clascoterone is currently licensed in the UK for acne vulgaris in people aged 12 years and over.
- NICE has not issued a positive or negative NHS recommendation because its technology appraisal ended without a company evidence submission.
- Treatment response varies, and the Phase III success rates should not be presented as guaranteed outcomes for an individual patient.
- Acne treatment should be individualised according to severity, lesion type, scarring risk, previous treatments, skin tolerance and patient priorities.
FAQs:
1. What is clascoterone cream used for?
Clascoterone 1% cream is a topical prescription treatment developed for acne vulgaris. It works by blocking androgen receptors within the skin, helping to reduce the hormonal signals that contribute to acne. This offers a different approach from many traditional acne treatments.
2. How does clascoterone differ from other acne treatments?
Unlike antibiotics or retinoids, clascoterone targets the effects of hormones directly within the skin. Clascoterone acts primarily within the skin by inhibiting androgen receptors and has low systemic exposure. This differs from systemic hormonal treatments, although topical treatment should not be described as completely incapable of producing systemic effects.
3. Why were the clascoterone clinical trials carried out?
The phase III clinical trials were designed to assess the safety and effectiveness of clascoterone 1% cream in treating acne vulgaris. Researchers compared the cream with a placebo (vehicle cream) to determine how well it reduced acne lesions and improved overall skin appearance. The findings supported its regulatory approval.
4. Who participated in the clascoterone studies?
The studies included both adolescents and adults with facial acne vulgaris. The pivotal Phase III studies enrolled people aged 9 years and over with moderate or severe facial acne vulgaris. The current UK licensed indication is for patients aged 12 years and over.
5. How did researchers measure whether the treatment worked?
Researchers counted inflammatory lesions, such as papules and pustules, as well as non-inflammatory lesions like blackheads and whiteheads. They also used standard clinical assessment tools to evaluate overall acne severity and skin improvement. These measurements allowed an objective comparison between treatment groups.
6. What were the main findings of the clascoterone trials?
The studies showed that clascoterone significantly reduced both inflammatory and non-inflammatory acne lesions compared with the vehicle cream. A higher proportion of participants receiving clascoterone achieved the strict IGA treatment-success endpoint than those receiving vehicle. The trials also found greater reductions in inflammatory and non-inflammatory lesion counts.
7. Is clascoterone considered a safe treatment?
The clinical trials found that clascoterone had an acceptable safety profile. The pivotal trials reported low adverse-event rates, with events predominantly mild and broadly similar to vehicle treatment. Current prescribing information also includes precautions relating to local reactions and potential systemic effects under certain exposure conditions, which your healthcare professional can discuss with you.
8. Can clascoterone be used with other acne treatments?
Yes, dermatologists may recommend using clascoterone alongside other evidence-based acne treatments when appropriate. Combination therapy can target different causes of acne, such as excess oil production, blocked pores, and inflammation. Your treatment plan should always be tailored to your specific needs.
9. Why is topical hormonal therapy important for acne?
Before clascoterone, hormone-related acne was mainly treated with oral medications. A topical anti-androgen allows hormonal activity to be targeted directly within the skin while acting primarily within the skin and producing low systemic exposure
This provides an additional option for patients who may not be suitable for systemic hormonal treatments.
10. Should I see a dermatologist if my acne is not improving?
If your acne is persistent, causing scarring, or affecting your confidence, it is advisable to seek specialist advice. A dermatologist can assess your skin, identify the underlying causes, and recommend the most appropriate treatment options. Early treatment may also help reduce the risk of permanent acne scars.
Final Thoughts: How Clascoterone Is Changing the Future of Acne Treatment
The pivotal clascoterone clinical trials marked an important advance in acne care by introducing the first topical anti-androgen therapy designed to target one of the underlying hormonal causes of acne directly within the skin. By demonstrating meaningful improvements in acne severity alongside a favourable safety profile, these studies expanded the range of evidence-based treatment options available for both adolescents and adults.
As our understanding of acne continues to evolve, treatment is becoming increasingly personalised, with therapies selected according to the underlying causes, severity, and individual needs of each patient. If you would like to book a consultation with one of our Dermatologist in London, you can contact us at the London Dermatology Centre.
References:
- Kim, H.J. and Kim, Y.H. (2024) ‘Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies’, International Journal of Molecular Sciences, 25(10), 5302. Available at: https://www.mdpi.com/1422-0067/25/10/5302
- Amuzescu, A., Tampa, M., Matei, C. and Georgescu, S.R. (2024) ‘Adult Female Acne: Recent Advances in Pathophysiology and Therapeutic Approaches’, Cosmetics, 11(3), 74. Available at: https://www.mdpi.com/2079-9284/11/3/74
- Hebert, A. et al. (2020) ‘Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials’, JAMA Dermatology, 156(6), pp. 621–630. Available at: https://pubmed.ncbi.nlm.nih.gov/32320027/
- Hebert, A. et al. (2023) ‘Efficacy and Safety of 1% Clascoterone Cream in Patients Aged ≥12 Years With Acne Vulgaris’, Journal of Drugs in Dermatology, 22(2), pp. 174–181. Available at: https://pubmed.ncbi.nlm.nih.gov/36745367/
- Sanchez, C. and Keri, J. (2022) ‘Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream’, Clinical, Cosmetic and Investigational Dermatology, 15, pp. 1357–1366. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9297041/